{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:55:03Z","timestamp":1790430903358,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002387","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002387","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gynecologic Oncology Group Administrative Office","award":["27469"],"award-info":[{"award-number":["27469"]}]},{"name":"Gynecologic Oncology Group Statistical and Data Center","award":["37517"],"award-info":[{"award-number":["37517"]}]},{"name":"NRG Oncology SDMC","award":["180822"],"award-info":[{"award-number":["180822"]}]},{"name":"NRG Oncology Operations","award":["180868"],"award-info":[{"award-number":["180868"]}]},{"name":"GOG Young Investigator Award."}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.ygyno.2015.07.103","type":"journal-article","created":{"date-parts":[[2015,7,26]],"date-time":"2015-07-26T14:04:38Z","timestamp":1437919478000},"page":"17-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology\/GOG study"],"prefix":"10.1016","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2053-8604","authenticated-orcid":false,"given":"James S.","family":"Ferriss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J.","family":"Java","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Bookman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Monk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard D.","family":"Homesley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin E.","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Boente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.07.103_bb0005","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0010","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1349-7006.2002.tb01302.x","article-title":"Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model","volume":"93","author":"Akutagawa","year":"2002","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0015","first-page":"89","article-title":"Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer","volume":"10","author":"Yabushita","year":"2003","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1158\/1541-7786.MCR-07-0366","article-title":"Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion","volume":"6","author":"Belotti","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7","article-title":"Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease","volume":"85","author":"Kraft","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.07.103_bb0030","first-page":"33","article-title":"Tumor angiogenesis in advanced stage ovarian carcinoma","volume":"147","author":"Hollingsworth","year":"1995","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0035","first-page":"587","article-title":"The prognostic significance of angiogenesis in epithelial ovarian carcinoma","volume":"5","author":"Alvarez","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0040","first-page":"2594","article-title":"Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor\/permeability factor neutralizing antibody","volume":"58","author":"Luo","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0045","first-page":"5224","article-title":"Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation","volume":"63","author":"Belotti","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0050","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0055","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0060","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA Open-Label Randomized Phase III Trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0065","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"365","key":"10.1016\/j.ygyno.2015.07.103_bb0070","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"29","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"365","key":"10.1016\/j.ygyno.2015.07.103_bb0075","first-page":"2484","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"12\/29","author":"Perren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0080","article-title":"Outcome differences in patients with stage IV epithelial ovarian, primary peritoneal and fallopian tube cancers treated with and without bevacizumab","author":"Randall","year":"2013"},{"key":"10.1016\/j.ygyno.2015.07.103_bb0085","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1991.9.7.1138","article-title":"Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience","volume":"9","author":"Omura","year":"1991","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0090","first-page":"2652","article-title":"Significant expression of vascular endothelial growth factor\/vascular permeability factor in mouse ascites tumors","volume":"58","author":"Luo","year":"1998","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2015.07.103_bb0095","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2012.05.002","article-title":"VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5","volume":"127","author":"Herr","year":"2012","journal-title":"Gynecol.Oncol."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0100","first-page":"5721","article-title":"Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model","volume":"9","author":"Byrne","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0105","doi-asserted-by":"crossref","unstructured":"Pearson K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philosophical Magazine Series 5 1900;50:157\u2013175.","DOI":"10.1080\/14786440009463897"},{"key":"10.1016\/j.ygyno.2015.07.103_bb0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1214\/aoms\/1177730491","article-title":"On a test of whether one of two random variables is stochastically larger than the other","volume":"18","author":"Mann","year":"1947","journal-title":"Ann. Math. Stat."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0115","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0125","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/1097-0258(20010130)20:2<237::AID-SIM654>3.0.CO;2-I","article-title":"Regression splines for threshold selection in survival data analysis","volume":"20","author":"Molinari","year":"2001","journal-title":"Stat. Med."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0130","series-title":"A Language and Environment for Statistical Computing","author":"R Core Team","year":"2013"},{"issue":"3","key":"10.1016\/j.ygyno.2015.07.103_bb0135","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ygyno.2014.03.574","article-title":"Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance","volume":"133","author":"Wimberger","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2015.07.103_bb0140","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2014.03.564","article-title":"MiR-378 as a biomarker for response to anti-angiogenic treatment in ovarian cancer","volume":"133","author":"Chan","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0145","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1158\/1078-0432.CCR-13-0489","article-title":"Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection","volume":"19","author":"Collinson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2015.07.103_bb0150","first-page":"32","article-title":"Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer","author":"Winterhoff","year":"2014","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815300883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T05:48:10Z","timestamp":1717998490000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815300883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0090825815300883"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.07.103","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: An NRG Oncology\/GOG study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.07.103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}